NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
New Therapeutic Window of Regenerative Opportunity in Diabetic Retinopathy by VESGEN AnalysisVascular pattern may serve as a useful new biomarker principle of complex, multi-scale signaling in pathological, physiological angiogenesis and microvascular remodeling. Each angiogenesis stimulator or inhibitor we have analyzed, including VEGF, bFGF, TGF-beta1, angiostatin and triamcinolone acetonide, has induced a novel "fingerprint" or "signature" biomarker vascular pattern that is spatio-temporally unique. Remodeling vasculature thereby provides an informative read-out of dominant molecular signaling, when analyzed by innovative, fractal-based VESsel GENeration (VESGEN) Analysis software. Using VESGEN to analyze ophthalmic clinical vascular images, we recently introduced a potential paradigm shift to the understanding of early-stage progression that suggests new regenerative opportunities for human diabetic retinopathy (DR), the major blinding disease for working-aged adults. In a pilot study, we discovered that angiogenesis oscillates as a surprising, homeostatic-like regeneration of retinal vessels during early progression of DR (IOVS 51(1):498). Results suggest that the term non-proliferative DR may be a misnomer. In new studies, normalization of the vasculature will be determined from the response of vascular pattern to therapeutic monitoring and treatment. We have mapped and quantified in vivo experimental models of angiogenesis, lymphangiogenesis and intravital blood flow from cellular/molecular to higher systems levels that include a murine model of infant retinopathy of prematurity (ROP); developing and pathological coronary and placental-like vessel models; progressive intestinal inflammation, growing murine tumors, and other pathological, physiological and therapeutically treated tissues of transgenic mice and avian embryos. Vascular Alterations, Visual Impairments (VIIP) & Increased Intracranial Pressure (ICP), Immunosuppression & Bone Loss: NASA-defined risk categories for human space exploration and ISS Utilization
Document ID
20130011704
Acquisition Source
Glenn Research Center
Document Type
Presentation
Authors
Parsons-Wingert, Patricia A.
(NASA Glenn Research Center Cleveland, OH, United States)
Date Acquired
August 27, 2013
Publication Date
September 13, 2012
Subject Category
Aerospace Medicine
Report/Patent Number
GRC-E-DAA-TN5927
Funding Number(s)
WBS: WBS 432938.11.01.03.02.02.19
Distribution Limits
Public
Copyright
Work of the US Gov. Public Use Permitted.
No Preview Available